Acquiring Company
Kohlberg Kravis Roberts
Acquired Company
HealthCare Royalty Partners (HCRx)
New YorkConnecticutEnergyFinancial ServicesReal EstateFinanceReal Estate InvestmentVenture CapitalAngel InvestmentRenewables & EnvironmentBiotechnologyDescription
KKR has expanded its healthcare portfolio by acquiring HealthCare Royalty Partners (HCRx), a leading asset manager with $3 billion in assets. The acquisition allows KKR to enhance its capabilities in biopharma royalties and structured financing. This move reflects KKR's commitment to addressing the growing capital needs of its clients. HCRx is known for its strong strategic and cultural fit with KKR's existing healthcare investment franchise.
Quick answer
Kohlberg Kravis Roberts is acquiring HealthCare Royalty Partners (HCRx), announced August 1, 2025. Kohlberg Kravis Roberts is based in New York, New York, United States.
- How much did Kohlberg Kravis Roberts pay for HealthCare Royalty Partners (HCRx)?
- The deal value was not disclosed.
- What does Kohlberg Kravis Roberts do?
- Kohlberg Kravis Roberts (KKR) is a leading global investment firm that manages multiple asset classes, including private equity, energy, infrastructure, real estate, and credit.
- Where are Kohlberg Kravis Roberts and HealthCare Royalty Partners (HCRx) based?
- Kohlberg Kravis Roberts is based in New York, New York, United States. HealthCare Royalty Partners (HCRx) is based in Connecticut, United States.
- Who are the decision-makers at Kohlberg Kravis Roberts?
- Fundz holds 5 contacts at Kohlberg Kravis Roberts. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Energy and Financial Services
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- KKR to acquire majority stake in HealthCare Royalty (August 15, 2025)
- KKR acquires Spectris PLC for £4.1 billion, $5.4B (July 2, 2025)
- KKR completes acquisition of Biotage shares (June 25, 2025)
- KKR fully acquires Samhwa for $528 million, $528M (September 4, 2025)
- KKR acquires sole control of Topcon Corporation (August 27, 2025)
- KKR acquires Metronet for fiber expansion (July 24, 2025)
Who to call at Kohlberg Kravis Roberts, and when
When Kohlberg Kravis Roberts changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Kohlberg Kravis Roberts raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kohlberg Kravis Roberts, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kohlberg Kravis Roberts. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kohlberg Kravis Roberts makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired HealthCare Royalty Partners (HCRx)?
HealthCare Royalty Partners (HCRx) was acquired by Kohlberg Kravis Roberts, based in New York. The deal was reported on August 1, 2025. Kohlberg Kravis Roberts (KKR) is a leading global investment firm that manages multiple asset classes, including private equity, energy, infrastructure, real estate, and credit. Kohlberg Kravis Roberts is publicly traded (KKR) and operates in Energy.
When did Kohlberg Kravis Roberts acquire HealthCare Royalty Partners (HCRx)?
Kohlberg Kravis Roberts's acquisition of HealthCare Royalty Partners (HCRx) was reported on August 1, 2025. KKR has expanded its healthcare portfolio by acquiring HealthCare Royalty Partners (HCRx), a leading asset manager with $3 billion in assets. The acquisition allows KKR to enhance its capabilities in biopharma royalties and structured financing. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does HealthCare Royalty Partners (HCRx) do?
Founded in 2006, HCRx is a leading asset management firm focused on investments in commercial-stage and near-commercial-stage biopharmaceutical assets. It has a strong track record of performance, having deployed over $7 billion in capital. It is privately held, operating in Biotechnology, and is based in Connecticut.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.